|
1
|
Hendriks LEL, Remon J, Faivre-Finn C,
Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G and Reck M:
Non-small-cell lung cancer. Nat Rev Dis Primers. 10:712024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu Z, Yang Q, Chen X, Zheng L, Zhang L, Yu
Y, Chen M, You Q and Sun J: Clinical associations and prognostic
value of site-specific metastases in non-small cell lung cancer: A
population-based study. Oncol Lett. 17:5590–5600. 2019.PubMed/NCBI
|
|
3
|
Huang Y, Zhu L, Guo T, Chen W, Zhang Z, Li
W and Pan X: Metastatic sites as predictors in advanced NSCLC
treated with PD-1 inhibitors: A systematic review and
meta-analysis. Hum Vaccin Immunother. 17:1278–1287. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu S, Pan Y, Mao Y, Chen Y and He Y:
Current progress and mechanisms of bone metastasis in lung cancer:
A narrative review. Transl Lung Cancer Res. 10:439–451. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li W, Guo Z, Zou Z, Alswadeh M, Wang H,
Liu X and Li X: Development and validation of a prognostic nomogram
for bone metastasis from lung cancer: A large population-based
study. Front Oncol. 12:10056682022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng Y, Wang PP, Fu Y, Chen YY and Ding
ZY: Zoledronic acid enhances the efficacy of immunotherapy in
non-small cell lung cancer. Int Immunopharmacol. 110:1090302022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Congedo MT, Nachira D, Bertolaccini L,
Chiappetta M, Zanfrini E, Meacci E, Vita ML, Lococo F, D'Argento E,
Spaggiari L and Margaritora S: Multimodal therapy for synchronous
bone oligometastatic NSCLC: The role of surgery. J Surg Oncol.
125:782–789. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng K, Liu X, Ji W, Lu J, Cui J and Li
W: The efficacy of different inflammatory markers for the prognosis
of patients with malignant tumors. J Inflamm Res. 14:5769–5785.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mukaida N, Sasaki S-I and Baba T:
Two-faced roles of tumor-associated neutrophils in cancer
development and progression. Int J Mol Sci. 21:34572020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fernandes Q, Inchakalody VP, Bedhiafi T,
Mestiri S, Taib N, Uddin S, Merhi M and Dermime S: Chronic
inflammation and cancer; the two sides of a coin. Life Sci.
338:1223902024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Yin L, Shen S and Hou Y:
Inflammation and cancer: Paradoxical roles in tumorigenesis and
implications in immunotherapies. Genes Dis. 10:151–164. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pęczek P, Gajda M, Rutkowski K, Fudalej M,
Deptała A and Badowska-Kozakiewicz AM: Cancer-associated
inflammation: Pathophysiology and clinical significance. J Cancer
Res Clin Oncol. 149:2657–2672. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gul B, Metintas S, Ak G, Yilmaz S and
Metintas M: The relationship between nutritional status and
prognosis in patients with locally advanced and advanced stage lung
cancer. Support Care Cancer. 29:3357–3365. 2021.PubMed/NCBI
|
|
14
|
Ruan GT, Ge YZ, Xie HL, Hu CL, Zhang Q,
Zhang X, Tang M, Song MM, Zhang XW, Liu T, et al: Association
between systemic inflammation and malnutrition with survival in
patients with cancer sarcopenia-A prospective multicenter study.
Front Nutr. 8:8112882021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang CL, Jiang XC, Li Y, Pan X, Gao MQ,
Chen Y and Pang B: Independent predictive value of blood
inflammatory composite markers in ovarian cancer: Recent clinical
evidence and perspective focusing on NLR and PLR. J Ovarian Res.
16:362023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Erciyestepe M, Selvi O, Dinç Sonuşen Ş,
Öztürk AE, Dinç G, Güneş TK, Aydın O, Yaşar N, Balkaya Aykut G and
Vatansever S: Prognostic value of inflammation and nutrition-based
scores in non-small cell lung cancer. Med Princ Pract. 33:122–132.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu L, Jiang R, Chen W, Liu Y, Wang G, Gong
X and Wang Y: Novel prognostic indicator combining inflammatory
indicators and tumor markers for gastric cancer. World J Surg
Oncol. 21:502023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu S, Cao S and Yu Y: High systemic
immune-inflammation index is a predictor of poor prognosis in
patients with nonsmall cell lung cancer and bone metastasis. J
Cancer Res Ther. 17:1636–1642. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Asano Y, Yamamoto N, Hayashi K, Takeuchi
A, Kato S, Miwa S, Okuda M, Matsumoto I, Yano S and Demura S: Serum
inflammatory dynamics as novel biomarkers for immune checkpoint
inhibitors in non-small-cell lung cancer with bone metastases.
Anticancer Res. 44:4493–4503. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li W, Qu Y, Wen F, Yu R, He X, Jia H, Liu
H and Yu H: Prognostic nutritional index and systemic
immune-inflammation index are prognostic biomarkers for
non-small-cell lung cancer brain metastases. Biomark Med.
15:1071–1084. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu S, Cao S, Geng J, Wang C, Meng Q and Yu
Y: High prognostic nutritional index (PNI) as a positive prognostic
indicator for non-small cell lung cancer patients with bone
metastasis. Clin Respir J. 15:225–231. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Canon J, Bryant R, Roudier M, Osgood T,
Jones J, Miller R, Coxon A, Radinsky R and Dougall WC: Inhibition
of RANKL increases the anti-tumor effect of the EGFR inhibitor
panitumumab in a murine model of bone metastasis. Bone.
46:1613–1619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng ML and Fong L: Effects of
RANKL-targeted therapy in immunity and cancer. Front Oncol.
3:3292014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen C, Song Z, Wang W and Zhou J:
Baseline anemia and anemia grade are independent prognostic factors
for stage IV non-small cell lung cancer. Mol Clin Oncol. 14:592021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jelkmann W and Hellwig-Bürgel T: Biology
of erythropoietin. Adv Exp Med Biol. 502:169–187. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Feng Y and Sun X: Recombinant
human erythropoietin accelerated the proliferation of non-small
cell lung cancer cell lines and reduced the expression of VEGF,
HIF-1alpha, and PD-L1 under a simulated hypoxic environment in
vitro. Chronic Dis Transl Med. 8:124–133. 2022.PubMed/NCBI
|
